Drugs / NK010
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07318636 | Jan → Dec 2026 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06676631 | Feb 2025 → Dec 2026 expected | lupus nephritis, systemic lupus erythematosus | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK010 | “NK010 is an allogeneic non-genetically modified NK cell infusion.” NCT06676631 ↗ |
| Modality | Cell therapy | “NK010 is an allogeneic non-genetically modified NK cell infusion.” NCT06676631 ↗ |
| Route | Intravenous | “NK010 will be administered intravenously in combination with a PD-1 antibody and platinum-based chemotherapy during the neoadjuvant treatment phase.” NCT07318636 ↗ |